Shows
Sanseakademiet21. Hjernepauser og hjælp til at komme tilbage til arbejdet efter sygdom. Interview med ergoterapeut Berit TherkelsenI denne episode har vi besøg af Berit Therkelsen, som er privatpraktiserende ergoterapeut med speciale i hjernetræthed og i at hjælpe mennesker tilbage i arbejde efter f.eks. stress eller længerevarende sygdom. Vi snakker om hjernepauser, vigtigheden af at være bevidst om sine egne sanseudfordringer, prioritering af energi og den svære kunst at italesætte behovet for pauser over for både sig selv, sine pårørende og arbejdspladsen.Berit deler ud af konkrete eksempler og fortæller om sit eget redskab – ”Min dag, min energi”, som gør det konkret over...
2026-02-2437 min
Sanseakademiet20. Børn og sanseforstyrrelser - hvornår er der brug for hjælp til at regulere arousalniveuaet?Vi kender alle til situationer med børn, der har svært ved at finde ro. Overalt er der meget fokus på, om et barn er sensitivt, og på hvornår der er brug for hjælp. Men hvordan man spotter man, når et barn er ude af balance med sine sanser? Som sundhedsfagligt personale er vigtigt altid at være nysgerrig på barnets adfærd og at huske på, at børn ikke er irriterende med vilje. I denne episode dykker vi dybere ned i, hvordan bevidsthed om sanserne og målrettet sansestimuleri...
2026-02-0329 min
OncLive® On AirMedical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC).
2026-01-2230 min
Sanseakademiet19. Fokus på sanserne er altafgørende for en god skoledag på specialskolen JeksendalI denne episode dykker vi ned i sansernes betydning for trivsel, læring og hverdagen i det hele taget for elever og personale på specialskolen Jeksendal. Vi har besøg af to meget dygtige og omsorgsfulde lærere Caroline Thøgersen og Jonathan Nielsen. De arbejder dagligt med elever, hvor sanserne fylder rigtig meget, og hvor det kræver både struktur, ro og en skarp faglighed at få skoledag til at lykkes, og for at det bliver en god oplevelse at komme i skole.Vi taler om, hvordan sanseintegration er en del af d...
2026-01-1341 min
2025-12-1735 min
Sanseakademiet18. Sansestimulering og bedre livskvalitet i demensplejen med Nanna ThulesenI denne episode har vi fokus på sansestimulering inden for demensplejen, og det gør vi allerbedst ved at snakke med Nanna Thulesen. Nanna er fysioterapeut, og har mange års virkelig god og praktisk erfaring med sansestimuli som tilgang og som værktøj i plejen af mennesker med demens. Nanna har en stor forståelse for kroppens samspil mellem nerver og hjerne, og hun deler gerne ud af sin viden både i undervisning af personalegrupper og her i podcasten. I podcasten kommer Nanna bl.a. med konkrete råd til, hvad man som sundhedsf...
2025-12-0936 min
Sanseakademiet17. Special episode on Jean Ayres, CLASI-education and helping children through knowledge on sensory integration with Dr. Zoe MaillouxIn this special episode, we are proud to announce a special guest - Dr. Zoe Mailloux – one of the world’s leading experts in Ayres Sensory Integration®.Zoe tells about working with Dr. Jean Ayres, how she was inspired to know more about sensory integration, and she shares her lifelong passion for helping children who struggle to process sensory information - children who find it hard to fit in, to focus, or to feel comfortable in everyday situations.With deep insight, she explains how understanding sensory integration can open new ways to support these children — helping...
2025-11-2541 min
Research To Practice | Oncology VideosHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersFeaturing an interview with Dr Erika Hamilton, including the following topics: General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00) Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11) Mechanisms of resistance to endocrine therapy (10:08) Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26) Other applications for PROTACs (24:24) Emerging data from the Phase III evERA trial (27:38) Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51) CME information...
2025-11-2058 min
Breast Cancer UpdateHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here.
2025-11-2058 min
Research To Practice | Oncology VideosHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders (Companion Faculty Lecture)Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics: Mechanisms of endocrine resistance; incidence of ESR1 mutations in breast cancer (0:00) Testing methods for ESR1 mutations in patients with breast cancer; therapeutic options for patients with ESR1-mutant breast cancer (3:59) General overview of proteolysis-targeting chimeras (PROTACs); comparison of PROTAC estrogen receptor (ER) degraders and selective ER degraders (7:39) Early-phase data with vepdegestrant monotherapy or in combination with CDK4/6 inhibitors in ER-positive, HER2-negative metastatic breast cancer (mBC) (11:54) Phase III VERITAC-2 trial of vepdegestrant versus fulvestrant in ER-positive, HER2-negative mBC previously treated with endocrine...
2025-11-1929 min
Oncology Today with Dr Neil LoveHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here.
2025-11-1958 min
Rule The Roost Podcast🎙️ NEW EPISODE ALERT: “Sticky Situations & Smart Solutions” 🐔Why did the chicken cross the road, roll in mud, and cross back? Because he was a dirty double-crosser! 😆We’re back in the Freehold studio for another episode of the Rule the Roost podcast by Flock Free—where bird control meets brains, laughs, and a little bit of stickiness.This week, we’re diving into our favorite invisible weapon: Surface ProTac. It’s clear, it’s tacky, it’s self-cleaning, and it keeps birds off your ledges, mailboxes, and balconies—without bothering people or hurting wildlife. 💪🐦✅ Easy to apply ✅ Rain-activated self-cleaning ✅ UV-enhanced...
2025-11-1808 min
Sanseakademiet16. Bedre trivsel for medarbejde og borgere på bosteder med Jette ReinewaldI Aarhus Kommune er der lavet et projekt på en række bosteder med fokus på bedre trivsel for både medarbejdere og borgere. De konkrete borgere på bostederne er både urolige, selvskadende eller viser udadreagerende adfærd, og det kan være svært at håndtere og påvirker selvfølgelig både borgernes og medarbejdernes hverdag.I projektet har både medarbejdere og borgere brugt sanserum og sansestimulerende hjælpemidler bl.a. kugledyner, kugleveste og kuglestole – og på bostederne har man oplevet, at borgerne bliver mere rolige, sover bedre og deltager mere aktivt i fæll...
2025-11-0422 min
谭勇品读医药风云谁在定义药企竞争力？(二）价值创造是指通过提供产品或服务，以及与之相关的商业活动，为顾客或其他利益相关者增加价值的过程。医药企业可概括为工业、商业、服务3类，为利益相关方提供药物制剂(化药、生物制品、中成药)、中间产品(原料药、中间体)、医疗器械(设备、耗材、IVD)、代理销售服务(CSO)、药物研产服务(CXO)、医疗服务等。经过改革开放后四十多年的快速发展，常规药械产品已取得了较充分发展，经过国家及地方集采的洗礼，在成本竞争下渐趋格局相对稳定的存量市场。医药增量市场在于以创新药械满足尚未满足的临床需求，取得竞争优势的关键是差异化、高效的产品创新。差异化是在底层机制、技术特征上与竞争者拉开身位，高效是在研发时间、研发费用、临床疗效上构筑竞争优势，通过两者结合跳出内卷式竞争。竞争力20强企业所属子行业分布中，50%为生化制药行业（10个）、20%为医疗器械行业（4个）、15%为中药行业（3个）、10%为生物制品行业（2个）、5%为医药商业（1个）。研发投入是产品(服务)创新的核心支撑，其规模、强度和结构直接影响创新产出，构成了公司的竞争力基石。对于存在创新药械研发活动的化学制剂、生物制品、医疗器械子行业，医药上市公司研发投入规模和强度呈现显著分化。20强公司的平均研发费用达到了17.91亿元，其中7家超过平均值。恒瑞医药作为创新药龙头，累计研发投入已突破440亿元，在2022-2024年均保持在60亿元以上，2024年研发投入以82.28亿元创历史新高。2024年，恒瑞医药的研发强度为29.4%，已超过全球制药巨头罗氏(24.5%)、强生(19.4%)。在研发投入结构上，恒瑞医药将90%以上的研发投入用于创新药研发，支撑其在肿瘤、自免等领域的规模和进度优势，2024年海外临床试验数量同比增长120%，体现了研发投入增长带来的成果。在高额研发投入的支持下，恒瑞医药在产品管线组合上采取横向广覆盖策略，不仅在核心的肿瘤领域建立了单抗、双抗、ADC、PROTAC、放射性药物等多种专有技术平台，同时布局代谢(如GLP-1/GIP双靶药物HRS9531)、自免领域(如PD-L1/TGF-β双抗SHR-1701)等领域。众多技术平台不仅可以单独产出特定模式的药物，而且可以通过跨平台技术协同产生更多组合式创新，如ADC平台和双抗平台协同产出双抗ADC药物。2025年竞争力20强揭榜，谁在定义药企竞争力？请您明天接着收听。
2025-10-1604 min
Sanseakademiet15. Gode råd om sanseintegration med Jette ReinewaldI denne episode giver ergoterapeut korte og gode råd til, hvordan fokus på sanseintegration kan afhjælpe adfærdsproblemer og øge trivslen hos mennesker i alle aldre. Jette tager altid udgangspunkt i, at søvn er afgørende for at trives i hverdagen, og hun fortæller derfor kort om søvn og søvnhygiejne og giver derfor en række eksempler fra hverdagen, som langt de fleste af os vil nikke genkendende til. Jette forklarer også, hvorfor det er vigtigt at have en fagligt funderet tilgang til sansestimule...
2025-10-1414 min
MDBros｜Paradigm Shifts in Healthcare生醫界的軍火商｜私募股權巨頭打造 CRDMO 航母 BioDuro-SundiaBioDuro-Sundia 是由全球頂級私募基金 Advent International 打造的 CRDMO 巨頭，透過策略性併購整合成從藥物發現到商業化生產的一站式平台，獨特的中美雙引擎佈局不僅優化研發成本，更在地緣政治風險下提供供應鏈韌性。擁有生物利用度增強、PROTAC、AI 輔助藥物發現等尖端技術平台，服務超過 1,500 家全球客戶，不僅具備與台灣國衛院成功合作的經驗，更在台設有研發中心，成為台灣創新走向國際的理想加速器。
--
Hosting provided by SoundOn
2025-10-071h 35
Sanseakademiet14. Kort om sanseintegration med Jette ReinewaldHer kan du hurtigt få et indblik i, hvad sanseintegration er, og hvor afgørende vellykket sanseintegration er for trivslen i din hverdag. Ergoterapeut Jette Reinewald giver en kort teoretisk introduktion og en lang række eksempler, som er let genkendelige fra hverdagen.Har du feedback eller spørgsmål, så skriv til os på protac@protac.dkProduceret af Protac A/SVært: Rikke HaarupGæst: Jette ReinewaldProducer og klipper: Pernille Sofie Karlsen...
2025-09-2313 min
Sanseakademiet13. Uddannelse og unge med skizofreni med Birthe BruunBirthe Bruun Olsen er specialergoterapeut og har igennem hele sin karriere haft særlig opmærksomhed på psykiatrien og de seneste år særligt på at hjælpe unge med skizofreni videre med livet. I podcasten fortæller hun om vigtigheden af at opbygge tillid til den unge og de pårørende, som forud har gennemgået en meget svær periode, og hun understreger vigtigheden af den tværsektorielle indsats, som skaber en ny bro af forståelse og hensyn til den unge, sådan at mødet med en ny hverdag og arbejdsgiver...
2025-09-021h 03
Sanseakademiet12. CE-mærkning med Trine DanielsenI denne episode af Sanseakademiet dykker vi ned i, hvad CE-mærkning egentlig betyder, og hvorfor det er helt afgørende, når det gælder sansestimulerende og beroligende hjælpemidler.Du møder Trine Danielsen, kvalitetsansvarlig hos Protac, som fortæller, hvordan Protac arbejder med dokumentation, sikkerhed og kvalitet – og hvorfor CE-mærkningen ikke bare er et klistermærke, men en sikkerhed for, at hjælpemidlerne lever op til de højeste standarder. Trine fortæller også om, hvad man skal holde særligt øje med som pårørende, bruger og fagperson.Hvordan testes hj...
2025-08-1220 min
This Week In Medicine8 11 2025Hi, This Week in Medicine, we will be discussing First we will be discussing articles in New England Journal of Medicine Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer Journal of American Medical AssociationAlteplase for Acut...
2025-08-1121 min
生物解码BioDecoderE10 分子胶水：蛋白红娘“撮合”蛋白质，攻克不可成药的癌症靶点Revolution Medicines (RevMed) 利用“分子胶”技术，成功靶向被称为“不可成药”的KRAS突变蛋白，在肺癌治疗中取得突破性临床进展，目前进入了三期临床。这些微小分子如同蛋白质世界的"红娘"，巧妙地撮合两个原本互不相识的蛋白质，开启了药物设计的全新思路。分子胶（Molecular Glue）是一种小分子化合物，通过诱导或增强两个蛋白质之间的相互作用来发挥作用，从而实现对靶蛋白的调控或降解。传统的小分子抑制剂通常是通过类似凹凸卡榫的结构与靶点结合，但很多致癌蛋白，比如KRAS突变，表面光滑，缺乏可以结合的位点，所以一直以来都难以成药。RevMed公司开发的分子胶药物，可通过“诱导临近”（induced proximity）的机制，像胶水一样把环孢素蛋白粘在RAS蛋白表面，从而有效阻断RAS与下游效应蛋白的结合。分子胶的发展起源于偶然发现。1983年环孢菌素A获批用于防止器官移植排斥反应，1991年"分子胶"概念首次由Stuart Schreiber教授提出。随后，雷帕霉素等相继获批上市。2010年，沙利度胺结合E3泛素连接酶cereblon的机制被发现，推动了分子胶的深入研究。而现在，AI和高通量蛋白组学的发展，也让我们能够更理性去设计分子胶，加速分子胶的设计与优化。这场分子尺度的精准干预，正在重塑我们对抗癌症的方式。(02:20) 解析分子胶：分子胶如何通过诱导蛋白质相互作用打开新型靶点空间(03:50) 靶向蛋白降解 vs. 小分子抑制剂：为什么蛋白降解技术有望成为癌症治疗的更优选择(09:54) 分子胶水与PROTAC的差异与相似之处(11:27)分子胶发展史：开创性的FK506研究，揭示免疫抑制剂的全新作用机制(16:46) 蛋白降解技术的现状与挑战：从抑制到设计的跨越(21:17) 臭名昭著的分子胶先驱 - 致畸药物反应停“沙利杜安”(25:09) 激活蛋白？调节基因表达？分子胶的仍待发掘的多功能潜力(27:54) 突破不可成药的KRAS突变，靶向治疗肺癌取得突破性进展(31:01) RevMed突破性的临床进展: pan-RAS抑制剂 RMC-6236(36:07) RevMed突破性的临床进展: KRAS G12D抑制剂 RMC-9805(38:43) AI如何助力分子胶设计: Monte Rosa和YDS Pharmatech的实践案例(44:23) 高通量蛋白质组学在分子胶水研发中的赋能作用(46:50) 我们是否已经有了足够的小分子库？新药研发最重要的问题是什么？[参考文献]Molecular glue (MG) history: Schreiber, Stuart L. "The rise of molecular glues." Cell (2021)RMC-6236 from RevMed: Schulze, Christopher J., et al. "Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS." Science (2023)RMC-9805 from RevMed: Weller, Caroline, et al. "A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors." Science (2025).MG from Monte Rosa: Petzold, Georg, et al. "Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition." Science (2025).MG from Wang Lab and YDS Pharma: Lin, Hanfeng, et al. "Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron." bioRxiv (2025).👥 本期嘉宾介绍🔬 可思叮：系统生物学博士，专注于高通量组学与疾病机制解析。目前在湾区一家生物技术公司从事科研工作，热衷于利用大数据解决生物医学难题🧠 小水博士：博士后研究员，研究神经退行性疾病中的细胞死亡机制，擅长干细胞类器官建模与活细胞成像。最近开始深度研究 AI 在生物医学中的应用。🧪 小橙：生物物理学博士，专注蛋白质与小分子相互作用。目前致力于蛋白降解剂的开发，希望推动AI在临床医学中的应用。🧬 JK：癌症生物学博士，目前专注基因编辑技术与新型癌症疗法，致力于开发更精准的生物医药工具。
2025-08-0150 min
Novità per il mondo dell'Oncologia62 - La via degli ormoniLa pathway che fa capo al recettore per gli estrogeni è ovviamente fondamentale nel trattamento del carcinoma mammario “luminal-like”. Le nuove conoscenze biologiche e la disponibilità di farmaci innovativi stanno rivoluzionando l’intero percorso di cura delle pazienti in fase metastatica.Proviamo a partire da lontano: la soppressione ovarica (o di altri organi produttori di estrogeni) può determinare la regressione del tumore mammario in alcuni casi. Gli antiestrogeni – eventualmente associati a analoghi del LHRH – e gli inibitori dell’aromatasi hanno progressivamente sostituito l’endocrinochirurgia. Con questi primi agenti si è consolidata la strategia dell’impiego sequenziale dei vari ormonoterapici, riuscendo così anche a postici...
2025-07-2509 min
Oncology On The GoAdvancements and Evolving Strategies in Breast Cancer Treatment at IBC EastIn this episode, CancerNetwork® spoke with breast oncologists Heather McArthur, MD; Erika Hamilton, MD; Hope Rugo, MD; and Paolo Tarantino, MD, PhD, about advances in breast cancer. These developments included recent drug approvals and ongoing research for therapeutic approaches, particularly in the areas of antibody-drug conjugates (ADCs) and CDK4/6 inhibitors, based on presentations they gave at the 25th Annual International Congress on the Future of Breast Cancer (IBC) East in New York City.
Initially, McArthur, Komen Distinguished Chair in Clinical Breast Cancer Research at the Harold C. Simmons Comprehensive Cancer Center, discussed immunotherapy use in high-risk triple-negative and H...
2025-07-2119 min
Sanseakademiet11. Hverdagen med Tourette - Interview med Sebastian Krejberg MelchiorI denne episode af Sanseakademiet har vi besøg af Sebastian Krejberg Melchior, som fortæller om sin hverdag med Tourettes syndrom, sensoriske tics, OCD - og om de strategier han har fundet frem til for at fungere i en hverdag med studie, venner, familie og musik og alt det, som andre unge på 23 år også gerne vil. Hvis du vil vide mere om Sebastian, kan du følge med og kontakte ham på hans Instagram: @touredlife_organicPodcasten går på sommerferie og er tilbage tirsdag d. 12. august 2025. Vi ø...
2025-06-171h 01
BioSpaceM&A Ticks Up, ASCO Excites and Vaccines Cause More DramaThe words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology’s annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech’s solid tumor bispecific BNT327. Elsewhere, Sanofi nabbed the year’s second-biggest buyout, picking up Blueprint for $9.5 billion, expanding its rare disease portfolio. And Regeneron plunked down up to $2 billion to license a dual GLP-1/GIP receptor agonist from Chinese biopharma Hansoh...
2025-06-0420 min
Sanseakademiet10. Autisme-spekteret - Hvordan kan fokus på sanserne hjælpe? med Britt Sampedro PilegaardSanseakademiets tiende episode handler om autisme. Børn og voksne med autisme har ofte en øget følsomhed over for sanseinput – og dermed et sansesystem som er konstant på overarbejde. Nogle oplever at reagere voldsomt på sanseinput, andre at reagere forsinket, og rigtig mange oplever, at de generelt reagerer anderledes, end omverdenen forventer. Fordi sansesystemet hurtigt bliver overvældet hos et menneske med autisme, er det vigtigt at vide, hvad man bliver yderligere påvirket af, og hvad der kan hjælpe til mere ro. Derfor handler denne episode om, hvordan diagnosen...
2025-06-0323 min
BiotechTV - NewsASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradationHe describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein degradation field in general.
2025-06-0211 min
ASCO Daily NewsDay 2: Top Takeaways From ASCO25Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence. Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode. Today's selection...
2025-05-3109 min
Sanseakademiet9. Sanseintegration og brugen af sanserum med Britt Sampedro PilegaardSanserum bruges til enten at dæmpe eller vække den mentale vågenhed (også kaldet arousal) hos mennesker med en sanseforstyrrelse. Sanserum har i mange år været en fast del af bosteder og på psykiatriske afdelinger og i dag ses de i stigende grad også som pauserum i det offentlige rum som f.eks. lufthavne, på skoler og uddannelsesinstitutioner og i store virksomheder. Et sanserum skal være en mental pause og i denne episode sætter vi fokus på, hvad man kan opnå ved at bruge et sanserum og...
2025-05-2020 min
OncLive® On AirInnovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER DegradationThis featured podcast includes a data review and candid conversation with 4 experts on challenges in the current treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) due to endocrine resistance. This session occurred during a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. ESR1 mutations are a critical mechanism of resistance, spurring the development of next-generation endocrine agents targeting these mutations. These agents including oral selective estrogen receptor degraders (SERDs) and agents with novel mechanisms, including proteolysis-targeting chimeras (PROTACs), which may offer potential improvements over current treatments. This progra...
2025-05-121h 17
Hacker AnthologyProtein Wars: The Undruggable GambitIn the high-stakes world of near-future biotech, Dr. Yael Mossé leads KOODAC, a scrappy multinational team racing to shatter the myth of the 'undruggable' protein and save children from the deadliest cancers. Haunted by patients lost to neuroblastoma and driven by the memory of Evan Lindberg, Yael pushes her team beyond the edge of scientific possibility to target the elusive MYCN protein with revolutionary PROTAC drugs. But every discovery comes at a price: shadowy sabotage from pharma giants, digital espionage, and the chilling specter of their cure being twisted into a designer bioweapon.
As global boardrooms and bio-labs erupt in i...
2025-05-0824 min
Sanseakademiet8. Sanseintegration – en vej til at opnå og fastholde uddannelse og job med Jette ReinewaldI Sanseakademiets ottende afsnit skal vi snakke om, hvordan fokus på sanserne kan hjælpe udsatte borgere tilbage på arbejdsmarkedet. Vi har i de seneste år fået et rigtig godt samarbejde med flere jobcentre, som kan se, at fokus på sanserne kan være en vej til at hjælpe udsatte borgere til en mere stabil hverdag. Det samme gælder udsatte unge på flere uddannelsesinstitutioner. Når vi hjælper borgerne til at få styr på sanserne, hjælper vi dem til bedre trivsel - og dermed energi og overs...
2025-05-0628 min
Sanseakademiet7. Hvordan kan sanseintegration hjælpe borgere med demens til mere ro og bedre trivsel med Britt Sampedro PilegaardSanserne, og den måde vi bearbejder og filtrerer sanseinput på, er grundlæggende for vores trivsel, vores funktionsniveau og vores måde at reagere på. Vi er dybt afhængige af vores sanser for at forstå sig selv og hele verden omkring os. For et menneske med demens kan det være svært at forstå både sig selv og verden omkring, fordi demens ofte er koblet sammen med en sanseforstyrrelse, og derfor bliver det svært at bearbejde sanseindtryk hensigtsmæssigt. Derfor er fokus på sanserne og arbejdet med sansestimulerin...
2025-04-2221 min
Sanseakademiet6. Hvordan kan fokus på sanseintegration afhjælpe søvnforstyrrelser? med Britt Sampedro PilegaardVi ved det alle sammen, vi sover ikke nok. Vi ved også, at det er afgørende for vores trivsel og sundhed at komme helt ned i den dybe søvn. Det er bare ikke altid så nemt, og især ikke for mennesker der lider af en sanseforstyrrelse.Vigtigheden af søvn og daglig trivsel er hele grundlaget for Protac og for udviklingen af Protac Kugledynen®. Derfor er sætningen, "hvordan er nattesøvnen?", stadig udgangspunktet for al den sparring vores konsulenter giver fagpersoner og brugere hver dag. I denne epi...
2025-04-0817 min
Sanseakademiet5. Hvordan kan sanseintegration hjælpe urolige børn til mere koncentration og bedre trivsel? med Britt Sampedro PilegaardSelvfølgelig skal børn bevæge sig en masse, men det bliver problematisk, hvis de bliver nødt til at bevæge hele tiden. Derfor har vi i denne episode fokus på at hjælpe urolige børn til bedre koncentration og trivsel. Et dansk masterprojekt i ergoterapi viser, at hver femte elev i indskolingen lider af en sanseforstyrrelse - og det forstyrrer både selve barnet, de andre børn, læringsmiljøet og lærerens arbejdsmiljø.Ved at have fokus på barnets sansebehov kan vi hjælpe barnet til me...
2025-03-2521 min
Sanseakademiet4. Historien bag Protac del 2: Interview med Pia ChristiansenHar du endnu ikke hørt episode 3? Så start der. Episode 4 er nemlig en direkte forlængelse af episode 3. I denne episode fortæller ergoterapeut og grundlægger af Protac, Pia Christiansen, om sin baggrund som ergoterapeut, og hvad uddannelsen har betydet for hendes tilgang til at udvikle både produkter og firma. Hun fortæller også om ordentlighed som en afgørende værdi og hvordan CE-mærkning og forskningsresultater altid har været en del af Protac.Har du feedback eller spørgsmål, så skr...
2025-03-1828 min
Sanseakademiet3. Historien bag Protac del 1: Interview med Pia ChristiansenEt stort ønske om at hjælpe patienterne på psykiatrisk afdeling til en bedre nattesøvn, udviklede sig til det, vi i dag kender som Protac Kugledynen® og Protac som firma. I episode 3 og 4 har vi inviteret ergoterapeut og grundlægger af Protac, Pia Christiansen, med i podcasten. I episode 3 fortæller hun om uddannelsen i sanseintegration, som satte gang i alle ideerne, og hvordan ideen til Protac Kugledynen® blev skabt, da hun kom hjem - og Protac blev en realitet som firma.Episode 4 er en direkte forlængelse af episode 3...
2025-03-1827 min
Sanseakademiet2. Sanseintegration, sanseforstyrrelser og diagnoser - hvordan hænger det sammen? Med Britt Sampedro PilegaardI andet afsnit af Sanseakademiet har jeg ergoterapeut Britt Sampedro Pilegaard med, og vi skal selvfølgelig fortsætte med at snakke om sansernes betydning for vores trivsel.I dag skal vi dykke dybere ned i sanseforstyrrelser og udvalgte diagnosegrupper, som kan være særligt ramt af sanseforstyrrelser.Britt fortæller mere om, hvordan man kan afhjælpe generne ved at have en sanseforstyrrelse, en diagnose eller en psykiatrisk lidelse.Har du feedback eller spørgsmål, så skriv til os på protac@protac.dk
2025-03-1121 min
Sanseakademiet1. Hvad er sanseintegration – og hvad betyder det for vores daglige trivsel? Med Britt Sampedro PilegaardI Sanseakademiets første afsnit får vi styr på de primære begreber fra Jean Ayres’ teori om sanseintegration, og snakker om hvordan vi med fokus på vores sanser kan opnå en bedre trivsel.Det er Britt Sampedro Pilegaard, som er ergoterapeut og konsulent hos Protac, som forklarer os begreberne og giver masser af genkendelige eksempler fra hverdagen.Vores individuelle sansebehov kan være med til at forklare uro, koncentrationsbesvær, søvnproblemer og rastløshed. Det er udfordringer, vi alle kender, men for de fleste af os er det heldigvis kun i period...
2025-03-1120 min
SanseakademietIntroduktionVelkommen til SanseakademietHer i podcasten kommer vi til at snakke om regulering af sanser, sansestimulation og hvordan bevidstheden om sansebehov kan medvirke til en højere livskvalitet hos alle mennesker.Har du feedback eller spørgsmål, så skriv til os på protac@protac.dkProduceret af Protac A/S Vært: Rikke HaarupProducer og klipper: Pernille Sofie Karlsen www.protac.dkNyhedsbrevLinkedInFacebookInstagram
2025-02-2001 min
Les Dossiers de la RédacVar : 600 participants pour une tentative de record de massage cardiaque à ToulUn record du monde dans la ligne de mire… Pour sensibiliser aux gestes de premiers secours… La tentative de la ville de Toulon, par le biais de l'association PROTAC… réunir plusieurs centaines de personnes, au même moment, pour pratiquer des massages cardiaques…La détentrice du record, c'est Nice… 1812 personnes, c'était en 2016…2eme Édition à Toulon… Et si le record paraît bien loin, l'important c'est de participer… Valentin Tricon s'est rendu au palais des sports qui aujourd'hui (18/12) vibrait au rythme des battements du cœur.Hébergé par Audiomeans. Vis...
2024-12-2001 min
pharmaphorum PodcastSeeking effective, safe treatment for all with precision dosingIn a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options.
Creating new medicines by enhancing protein function, Richon is driven by the desire to bring drugs to these patients. She and Comstock discuss protein inhibition in comparison to protein enhancement, based on the idea that many diseases are caused by too little of a certain protein – for instance, a...
2024-12-1131 min
Rx for BiotechHow Arvinas is Transforming Cancer and Neuroscience Therapies: An Interview with CBO, Randy Teel, PhDArvinas is a biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. In this podcast episode, Dr. Randy Teel discusses the company's PROTAC protein degrader technology platform and its pipeline of clinical-stage assets, with a focus on vepdegestrant, the company's lead asset that is being co-developed together with partner Pfizer, for the treatment of women with early and locally advanced or metastatic ER+/HER2- breast cancer.
2024-12-0335 min谭勇品读医药风云10倍股“小恒瑞”累并奔跑着（三）近两年的年报中，海思科一直强调“不进行利润分配”，留存的未分配利润则“将主要用于支持公司日常经营发展、研发投入及流动资金需要，保障公司正常生产经营和稳定发展，增强抵御风险的能力，进一步提升公司核心竞争力。” 这些钱没有白花，给公司带来了亮眼的回报，标志性事件共有三起：2020年12月，海思科研发的1类静脉麻醉药物环泊酚注射液（思舒宁）获批上市，并在次年的医保谈判中顺利晋级国家医保目录。截止2023年末，环泊酚注射液全部适应证均进入了国家医保目录，当年收入达到8.5亿元。同时该药也在开展国际化工作，在美国的两项Ⅲ期临床试验均已完成，将在美国申报NDA。2021年3月，海思科控股三级子公司FT集团与美国风投公司设立的一家非上市公司签署交易协议，将FT控股全部股权转让给该公司。FT集团有望获得最高合计1.8亿美元的转让款。2023年11月，海思科宣布旗下全资子公司与意大利凯西制药达成协议，将旗下一产品在大中华区外的权益有偿许可给该公司。海思科将收到1300万美元的首付款，且有望获得最高合计4.62亿美元的价款，以及获得实际年净销售额最高两位数的销售提成。新药放量，出海告捷，标志着海思科近几年完成了由仿到创的华丽转型，恰好还及时弥补了集采带来的冲击。今年，海思科又收获了一系列果实。5月和6月，神经痛药物思美宁两项适应证获批；6月，长效降糖新药考格列汀片（倍长平）获批上市；9月，HSK21542注射液（思舒静）新适应证获批上市，这一款外周选择性κ阿片受体激动剂，本次获受理的是用于治疗成人维持性血液透析患者的慢性肾脏疾病相关的中度至重度瘙痒适应症的上市许可申请。可以看到，目前海思科构筑起了一条麻醉镇痛产品组成的创新药护城河，由于多数属于管制药品，准入壁垒较高，赛道参与者较少，红利正在释放，成功对冲了仿制药带量采购的风险。尽管又在麻醉镇痛建立了相当的优势，但这远远无法抚平海思科一贯的危机感。于是在原来的空间之外，海思科又开辟了一块新的空间——靶向蛋白降解嵌合体技术，这也构成了海思科400多亿市值的重要一角。如果将这些药企看成中国的创新舰队，海思科将是靶向蛋白降解嵌合体（PROTAC）冲锋队的一员大将。这几年的年报中，海思科一直在强调自己在此方面的能力，表示“新药化学团队主要以海归博士、国内一流院校硕博士生为主的约100余位研究人员组成，其中博士17人，硕士及以上学历占比超过74%……重点搭建了靶向蛋白降解嵌合体、多肽偶联药物技术和计算机辅助药物设计等药物化学平台，在多个适应证领域取得重大进展。团队未来将围绕临床未满足需求方向，基于两个先进的平台，设计合成发现FIC和BIC类型的新型药物分子。海思科到底是如何在每一个阶段都抓住了机遇？他未来还有上涨空间吗？请您明天接着收听。
2024-11-0704 min
Research To Practice | Oncology VideosHR-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer (Companion Faculty Lecture)Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics: Targeted therapies for ER-positive breast cancer (0:00) Clinical data with oral selective estrogen receptor degraders (2:13) Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07) Emerging data with PROTACs for ER-positive advanced breast cancer (9:17) Future directions with PROTACs for breast cancer (19:21) CME information and select publications
2024-10-2522 min
Research To Practice | Oncology VideosHR-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerFeaturing an interview with Dr Erika Hamilton, including the following topics: Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00) Clinical evidence available with oral selective estrogen receptor degraders (3:46) Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22) PROTACs currently in clinical development (16:39) Case: A woman in her late 30s with HR-positive, HER2-negative metastatic breast cancer (mBC) experiencing progression on a CDK4/6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) (35:09) Case: A woman in her early 70s with HR-positive, HER2-negative mBC that progresses on a CDK4/6i and an AI (41:16) CME information and select publications
2024-10-2545 minBreast Cancer UpdateOncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerDr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.
2024-10-2545 min
Oncology Today with Dr Neil LovePotential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here.
2024-10-2545 min
Beyond Biotech - the podcast from LabiotechHarnessing the body’s natural targeted protein degradation system to treat diseasesC4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-stage biopharmaceutical company is dedicated to creating a new generation of medicines using its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. TORPEDO can design molecular glues and heterobifunctional degraders, giving C4T the capability of targeting almost any disease-causing protein. C4T’s degrader medicines are designed to harness the body’s natural protein recycli...
2024-09-2734 min
Progress, Potential, and Possibilities Podcast / ShowDr. Ryan Potts, Ph.D. - VP and Head, Induced Proximity Platform, Amgen - Leading The Next Wave Of Innovation In Drug Discovery, To Modulate Any Target, Every TimeSend a textDr. Ryan Potts, Ph.D. is Vice President and Head, Induced Proximity Platform at Amgen ( https://www.amgen.com/science/research-and-development-strategy/multispecifics-and-other-modalities ) which is focused on novel ways to bring two or more molecules in close proximity to each other to tackle drug targets that are currently considered “undruggable.” He also leads Amgen’s Research & Development Postdoctoral Fellows Program ( https://www.amgen.com/science/scientific-community-initiatives/postdoctoral-fellows ).Dr. Potts obtained his B.S. in Biology from the University of North Carolina and his Ph.D. in Cell and Molecular Biology from UT Southwestern in 200...
2024-08-0958 min
ASGCT Podcast NetworkTargeting STAT3 in Tumors with Oligo-PROTAC with Dr. Marcin Kortylewski—The Molecular Therapy PodcastJoin ASGCT and the Molecular Therapy family of journals for a conversation between Drs. Paloma Giangrande and Marcin Kortylewski. They discuss a recent article published in Molecular Therapy Nucleic Acids by Dr. Kortylewski and colleagues titled "Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3." If you enjoy today’s conversation, you’ll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24. This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolv...
2024-07-0934 min
BioTech BreakdownPROTAC - A Protein Purge SystemJoin me as we dive into the mechanisms behind PROTACs, a system to target and degrade proteins specifically!
2024-06-2605 min
S&S On Biotech3.3 Where have all the PROTACs gone?A couple of years ago, PROTACs were ubiquitous. Start-ups were devising increasingly clever ways of making them, while large pharma companies were queuing up to tap into their expertise and their development programs. Proteolysis-targeting chimeras, to give them their full title, emerged as a clever and versatile way of degrading, with exquisite selectivity, disease-associated proteins that were hard to drug by conventional means. First described over two decades ago, by Kathleen Sakamoto, Raymond Deshaies, and Craig Crews, they comprise ‘heterobifunctional’ small molecule drugs that bind a protein of interest at one end and an E3 ubiquitin ligase at th...
2024-05-1627 min谭勇品读医药风云恒瑞医药披露2023年年报（二）4月17日晚，恒瑞医药发布2023年年度报告。报告显示，恒瑞医药业绩稳步回升，创新驱动收入增长。2023年，恒瑞医药在研管线快速推进。报告期内，12项临床推进至Ⅲ期，35项临床推进至Ⅱ期，30项临床推进至Ⅰ期，公司有90多个自主创新产品正在临床开发，近300项临床试验在国内外开展。2023年至今，恒瑞医药共取得7项CDE突破性治疗品种认定，未来审批有望加速，其中仅公司HER2 ADC明星产品就独得5项；公司自主研发的首个小核酸药物注射液用于慢性乙肝获批临床，国内外暂无同类产品获批上市；恒瑞医药在核药领域布局的首对放射性精准治疗产品获批临床，目前公司已有4款核药获批开展临床试验。这些创新成果的取得，离不开恒瑞医药多年来打造的日益完备的创新体系。首先，经过多年发展，恒瑞医药已形成了一支5000多人的规模化、专业化、能力全面的研发团队，先后在连云港、上海、苏州、成都、厦门、济南、广州、北京、美国和欧洲等地设立了研发中心，满足多个疾病领域管线对新分子实体的发现和开发需求。其次，公司以“临床未满足的需求”为导向，以“新、快、特”为主要宗旨，坚持“差异化”的竞争策略，持续聚焦靶点前移，加强源头创新。恒瑞医药在肿瘤领域有丰富的研发管线，同时在自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域也进行了广泛布局。第三，公司还建立了一批具有自主知识产权、国际领先的新技术平台，如蛋白水解靶向嵌合物（PROTAC）、分子胶、抗体药物偶联物（ADC）、双/多特异性抗体、AI分子设计、体内药理、分子动力学、生物信息等，并不断优化和发展，为创新研发和国际化提供强大的基础保障。第四，已有11个新型、具有差异化的ADC分子成功获批临床。有的已快速进入临床Ⅲ期研究阶段；有的快速推进多项临床Ⅲ期研究，新一代双抗产品已顺利开展临床研究，还有10多个双/多特异性抗体在研。与此同时，恒瑞医药继续稳步推进国际化战略，坚持自主研发与开放合作并重，在内生发展的基础上加强国际合作。公告显示，恒瑞医药正以全球化的视野积极探索与跨国制药企业的交流合作，寻求与全球领先医药企业的合作机会。2023年，恒瑞医药按下BD加速键，共达成了总交易金额超40亿美元的5项授权合作。其中公司将两款抗癌创新药独家许可给德国默克，交易总金额可超14亿欧元，这也是恒瑞医药首次与全球大型跨国药企合作。目前恒瑞医药已实现10项创新药海外授权。恒瑞医药首个国际多中心Ⅲ期临床研究——卡瑞利珠单抗联合阿帕替尼治疗晚期肝癌国际多中心Ⅲ期研究已达到主要研究终点，在美国申报上市已经获得FDA正
2024-04-2605 min
起朱楼宴宾客vol.62.和一线创新药企早研科学家，聊聊这两年生物医药行业究竟发生了什么？大家好，我是大卫翁，“起朱楼宴宾客”是我用来记录这个大时代的播客节目。年末季策划的行业模块，另一个需要单开一期节目的自然就是我最爱的生物医药行业。过去两年对于这个行业来说并不是好年份，在经历了2018-2021年的极速发展后，至少从资本市场表现来看，这个行业迎来了至暗时刻。那么，是不是所有的问题都应该归结为资产泡沫？行业自身的发展进度如何？未来又会有什么样的趋势？很高兴这次能请到一位在一线药企做早期研发的科学家朋友小P，和我畅聊这两年生物医药行业在研发端究竟发生了什么。必须和各位说声抱歉的是，这期节目里确实有着大量的术语名词，就算对于我这么一个持续关注行业的人来说也是有够吃力。目前这期节目的文字稿已经在公众号上发布，感兴趣的朋友可以移步阅读：《生物医药行业，做得越多，错得越多？》最后必须说的是，健康和长寿是人类的基本追求，而生物医药行业的则是实现这个追求的必经之路，所以无论于情于理，我都会持续关注和投资这个行业。但这个行业正在变得和过去十年完全不同，无论是专业性还是前瞻性都在高速发展，因此对于我们的投资姿势提出了更高的要求——要么就是指数化，要么就是找更加专业的基金经理，几乎别无他法。简易时间轴：WARM UP环节02:06 早研科学家究竟是做什么的？PART 1 过去两年生物医药行业究竟发生了什么？07:17 行业的关键转折点：PD-1和mRNA这两个重金投入的技术没有延续过去几年的奇迹08:00 PD-1：在它之后，再无奇迹15:40 mRNA：还在苦苦寻找进一步证明自己的应用场景18:30 CART：光芒出现，但成本是最大的制约因素PART 2 展望未来，行业有哪些新的趋势值得关注？26:20 ADC药物：临床实验展现出令人惊艳的结果，且是中国企业展现工程化能力的最佳平台31:30 插曲：在生物医药行业，为何小公司往往比大企业更容易取得前瞻技术上的突破？35:10 双抗平台：新药可以快速上市展现出监管和行业对其的重视程度38:00 Protac：无需理解蛋白结构也可以利用靶点的技术平台39:10 GLP-1：说到这两年的明星技术，怎能不提减肥神药？PART 3 什么样的药企才是最值得去工作，以及最值得投资的？42:30 大卫翁荐书时间：《十亿美元分子》44:20 小P心中的最佳药企：基因泰克46:10 一个药企的融资能力是给小P这样的科学家提供探索未知与引领资格的必备条件此外，如果想要用指数投资方式投资医药行业的话，可以参考我这一篇：《港股指数基金硬核投资指南》，里面对于几个不同的创新药指数以及对应的指数基金有比较具体的介绍。例如恒生医药ETF（159892），或是港股市场上的华夏恒生生科（03069.HK），作为目前市场上投资于港股创新药板块最大的ETF指数基金，是可以非常完整的覆盖中国目前最优秀的创新药企业群体的，但此处没有任何的投资建议。欢迎大家关注我的新的生活方式播客节目《犬生活》，《只要你也爱ever 17这样的galgame，我们就是好朋友｜串台边角聊》新鲜出炉！欢迎听众加入我的知识星球，我正在好好运营那一片后花园~欢迎在评论区和我互动，或者给我写邮件，邮箱地址qizhulouyanbinke@gmail.com。节目后期制作：Siri节目封面：Ximalaya AI
2024-01-2850 min
大卫翁vol.62.和一线创新药企早研科学家，聊聊这两年生物医药行业究竟发生了什么？
大家好，我是大卫翁，“起朱楼宴宾客”是我用来记录这个大时代的播客节目。
年末季策划的行业模块，另一个需要单开一期节目的自然就是我最爱的生物医药行业。
过去两年对于这个行业来说并不是好年份，在经历了2018-2021年的极速发展后，至少从资本市场表现来看，这个行业迎来了至暗时刻。
那么，是不是所有的问题都应该归结为资产泡沫？行业自身的发展进度如何？未来又会有什么样的趋势？
很高兴这次能请到一位在一线药企做早期研发的科学家朋友小P，和我畅聊这两年生物医药行业在研发端究竟发生了什么。
必须和各位说声抱歉的是，这期节目里确实有着大量的术语名词，就算对于我这么一个持续关注行业的人来说也是有够吃力。目前这期节目的文字稿已经在公众号上发布，感兴趣的朋友可以移步阅读：
《生物医药行业，做得越多，错得越多？》
最后必须说的是，健康和长寿是人类的基本追求，而生物医药行业的则是实现这个追求的必经之路，所以无论于情于理，我都会持续关注和投资这个行业。但这个行业正在变得和过去十年完全不同，无论是专业性还是前瞻性都在高速发展，因此对于我们的投资姿势提出了更高的要求——要么就是指数化，要么就是找更加专业的基金经理，几乎别无他法。
简易时间轴：
WARM UP环节
02:06 早研科学家究竟是做什么的？
PART 1 过去两年生物医药行业究竟发生了什么？
07:17 行业的关键转折点：PD-1和mRNA这两个重金投入的技术没有延续过去几年的奇迹
08:00 PD-1：在它之后，再无奇迹
15:40 mRNA：还在苦苦寻找进一步证明自己的应用场景
18:30 CART：光芒出现，但成本是最大的制约因素
PART 2 展望未来，行业有哪些新的趋势值得关注？
26:20 ADC药物：临床实验展现出令人惊艳的结果，且是中国企业展现工程化能力的最佳平台
31:30 插曲：在生物医药行业，为何小公司往往比大企业更容易取得前瞻技术上的突破？
35:10 双抗平台：新药可以快速上市展现出监管和行业对其的重视程度
38:00 Protac：无需理解蛋白结构也可以利用靶点的技术平台
2024-01-2850 min
The Protector Culture Podcast with Jimmy GrahamThe Protector Culture Podcast with Jimmy Graham Ep. 104: Holiday EDC Gift IdeasEvery year we get asked what are some gifts I can get for my spouse. In this episode we answer that question with a couple different gift ideas from a fidget toy for adults to a brand new rifle and everything in between! We hope these ideas are some sweet stocking stuffers. Provoke Karambit CRKT - https://www.amazon.com/CRKT-Provoke-Orange-Kinematic-Folding/dp/B08KDL634S/ref=sr_1_6?crid=1TTE648E95KDP&keywords=provoke+CRKT&qid=1702155177&sprefix=provoke+crkt%2Caps%2C125&sr=8-6 Leatherman K2 - https://www.amazon.com/LEATHERMAN-Free-Multitool-Knife-Gray/dp/B07P5...
2023-12-0939 min
Pearl Snap TacticalEDC in the Urban Jungle: Your Essential GuideWelcome to the (Urban) Jungle!!In today's fun packed episode, Alex and I delve into the urban jungle with an exploration of Urban EDC Essentials. For those of us seeking a sense of security and preparedness in our daily lives, understanding the essential everyday carry (EDC) items is paramount. Join us as we unpack the must-have tools and gear that empower us to navigate the challenges of urban living with confidence and peace of mind. Whether you're a seasoned urban tactician or new to the concept of EDC, this episode promises valuable insights a...
2023-10-1150 min
サイエンマニア伝われ！味わい深さ！「フォトレドックス触媒の反応」と「生物をハックするPROTAC」【ケミカルトーク 後編】#118化学者の今熱いトピックは止まらない。有機化学者にしかほぼ伝わらない話題に始まり、化学の面白さを伝える方法や工夫など、現役化学者ならではの悩み（？）もおしゃべりしました。
【ゲスト】
けむすい さん (Twitter: https://twitter.com/Chem_Wednesday)
misoさん（Twitter: https://twitter.com/misoram03621311）
編集協力 misoさん
【Twitter】
#サイエンマニア で感想お待ちしてます！番組情報も更新中。
【公式サイト】
番組へのおたよりやプロフィールはこちらから→ https://scientalkclub.wixsite.com/scienmania
おたよりはメールでも募集しています。 scientalkclub@gmail.com
ポッドキャストのフォローやレビューいただけると嬉しいです。
【サイエンマニアについて】
あらゆる分野のゲストを招き、サイエンスの話題を中心にディープでマニアな話を届けるポッドキャスト。
研究に夢中な大学院生や趣味を突き詰めている方まで、好きな事を好きなだけ語りたい人が集まる番組です。
第3回 Japan Podcast Awards 2021 推薦作品
【プロフィール】
研究者レン from サイエントーク
化学と生命科学が専門のおしゃべり好き研究者。サイエンスをエンタメっぽく発信するために様々な形で活動中。ポッドキャスト「サイエントーク」ではOLエマと共に番組を制作中。
Twitter: https://twitter.com/REN_SciEnTALK
Note: https://note.com/ren_scientalk/
【サイエントーク】
おしゃべりな研究者レンと普通のOLエマが科学をエンタメっぽく語るポッドキャスト番組です。
https://scientalkclub.wixsite.com/scientalk
【BGM】
DOVA-SYNDROME
2023-06-2733 min
The antibody-based pharmaceuticals resource library’s PodcastPROTAC Technology in Tumor Targeted TherapyToday, we will explore the protac technology applied in tumor-targeted therapy. The following will be presented to you, such as a brief introduction to Protac, the mechanism of action, the advantages and disadvantages of protac as a drug, and the core content: the application of protac technology in tumor therapy. And the last part, the protac solutions provided by Creative Biolabs. If you have any questions about the PROCT development, please email us.
2023-03-0209 min
Antibody-based pharmaceuticals resourcePROTAC Technology in Tumor Targeted TherapyToday, we will explore the protac technology applied in tumor-targeted therapy. The following will be presented to you, such as a brief introduction to Protac, the mechanism of action, the advantages and disadvantages of protac as a drug, and the core content: the application of protac technology in tumor therapy. And the last part, the protac solutions provided by Creative Biolabs. If you have any questions about the PROCT development, please email us.
2023-03-0209 min
PubReadingPubReading [256] - A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications - P. Stacey, M. Muelbaier et al.Targeted protein degradation is an emerging new strategy for the modulation of intracellular protein levels with applications in chemical biology and drug discovery. One approach to enable this strategy is to redirect the ubiquitin–proteasome system to mark and degrade target proteins of interest (POIs) through the use of proteolysis targeting chimeras (PROTACs). Although great progress has been made in enabling PROTACs as a platform, there are still a limited number of E3 ligases that have been employed for PROTAC design. Herein we report a novel phenotypic screening approach for the identification of E3 ligase binders. The key concept un...
2023-01-0330 min
Pest Geek PodcastThe Streamlight Protac 1L 1AA Carry Light Product Review By Wildlife Control Consultant Stephen Vantassel.This super bright dual fuel tactical flashlight is the perfect everyday carry light. It accepts a single lithium or alkaline battery, providing ultimate flexibility in the field to ensure professionals always have a beam when needed. On today’s edition of the Living The Wildlife podcast, host and wildlife control consultant Stephen Vantassel reviews the PROTAC®…
2022-10-0128 min
Evolution Security PodcastEp. 87 Gear and Mindset show 8 - EvoSec EDC and Body ArmorAaron Davis begins the show by reading an article about the lefts attempt to start banning body armor after some recent high profile mass murders were armor was worn by the killer, specifically Buffalo Body armor can protect all of us incase of a home invasion, mass chaos, riots, or simply civilians want to wear incase their locale is super dangerous. But to the left, they see it as too much liberty and they want to ban it for civilians yet maintain it specifically for the Government. Then the crew go over their main chest rigs. https://ww...
2022-09-131h 27
VJHemOnc PodcastAn insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDsMultiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including CAR-T therapy and T-cell engagers, are providing hope for patients, and novel targets are continuously being explored, especially in the relapsed/refractory setting.
In this exclusive podcast, leading experts Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, and Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discuss novel targets in multiple myeloma, including RAS and PIKfyve, and further comment on the epigenomics and epigenetics of resistance to proteasome inhibitors and IMiDs, as...
2022-07-1516 minVJHemOnc PodcastAn insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDsMultiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including CAR-T therapy and T-cell engagers, are providing hope for patients, and novel targets are continuously being explored, especially in the relapsed/refractory setting.
In this exclusive podcast, leading experts Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, and Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discuss novel targets in multiple myeloma, including RAS and PIKfyve, and further comment on the epigenomics and epigenetics of resistance to proteasome inhibitors and IMiDs, as...
2022-07-1516 min
Bringing Chemistry to LifeDrugging the undruggableVisit https://thermofisher.com/bctl to register for your free Bringing Chemistry to Life T-shirt and https://www.thermofisher.com/chemistry-podcast/ to access the extended video version of this episode and the episode summary sheet, which contains links to recent publications and additional content recommendations for our guest. You can access the extended video version of this episode via our YouTube channel to hear, and see, more of the conversation!Chemical biology is a relatively recent discipline where thinking about biomolecules as big organic molecules isn’t shocking, but it was completely revolutionary just 3 or 4 decades ago...
2022-06-2234 min
Molecular Modelling and Drug DiscoveryBayesian Optimization for Ternary Complex Prediction - Noah WeberIf you enjoyed this talk, consider joining the Molecular Modeling and Drug Discovery (M2D2) talks live: https://valence-discovery.github.io/M...
Also consider joining the M2D2 Slack: https://join.slack.com/t/m2d2group/sh...
Abstract: Proximity-inducing compounds (PICs) are an emergent drug technology through which the protein of interest (POI) is brought into the vicinity of proteins that control various cellular processes, giving rise to therapeutic benefits. One of the best-known PICs examples are heterobifunctional molecules known as proteolysis targeting chimeras (PROTACs), which induce protein degradation by establishing proximity between a P...
2022-05-2247 min
Act4Gaz radioLe bruit, il frappe sans crier gare !Un sujet dont on entend peu parler… le bruit ! Au travail, il peut représenter un risque pour notre santé mais aussi être cause de fatigue, de stress et d’autres troubles. En empêchant de se concentrer, le bruit nuit aussi à la qualité du travail. Retrouvez l’interview de Thomas Garrel, Directeur Commercial de la société Protac by Prodways qui nous en dit plus au micro d'Act4gaz Radio.
2021-12-1704 min
From Lab to Launch by QualioTreating previously undruggable diseases with Dr. Ian Taylor, CSO at ArvinasMost likely everyone reading this has been affected by cancer or knows someone who has had cancer. Using natural cell degradation, today's guest and the team at Arvinas are treating previously undruggable diseases like cancer and Parkinson's. Their goal is to cure cancer or at a minimum, reduce it to a disease where you take your medication and continue living a full life without the terrible side effects of today's treatments. Dr. Ian Taylor, Chief Science Officer at Arvinas, explains how his team is accomplishing this with PROTAC. Arvinas is a clinical-stage biopharmaceutical company focused on developing ne...
2021-10-2829 min
AgTech360Small Molecule Chemistry and Biotechnology with Oerth BioJohn Dombrosky of Oerth Bio, a young AgTech start-up in the Triangle of Raleigh, NC, talks about leveraging their proprietary PROTAC® protein degraders that work by harnessing the plant's own natural protein disposal system to degrade and remove unwanted proteins.@AgTech360agtech360@gmail.comgo.ncsu.edu/CERSAsouthernipm.org
2020-11-0923 min
AgTech360Small Molecule Chemistry and Biotechnology with Oerth BioJohn Dombrosky of Oerth Bio, a young AgTech start-up in the Triangle of Raleigh, NC, talks about leveraging their proprietary PROTAC® protein degraders that work by harnessing the plant's own natural protein disposal system to degrade and remove unwanted proteins.@AgTech360agtech360@gmail.comgo.ncsu.edu/CERSAsouthernipm.org
2020-11-0823 min
AgTech360Harnessing Plant Proteins with Oerth BioJohn Dombrosky of Oerth Bio, a young AgTech start-up in the Triangle of Raleigh, NC, talks about leveraging their proprietary PROTAC® protein degraders that work by harnessing the plant's own natural protein disposal system to degrade and remove unwanted proteins.
2020-11-0623 min
SanseLabSleep tightHar du hørt om kugledynen?
vidste du at det er en dansk ergoterapeut der har opfundet den?
i denne episode snakker jeg med Pia Christiansen, som er ejer af virksomheden Protac.
Pia fik sammen med en kollega i 90'erne en smadder god ide, de puttede nemlig tunge bolde i et dynebetræk og skabte den første kugledyne.
sidenhen har flere evidensbaserede studier bakket de resultater de så op, og Protac fortsætter med at udvikle skønne og spændende sanseintegrations hjælpemidler til dem der har brug for lidt ekstra hjælp i hverdagen.
du kan finde mer...
2020-09-2149 min
Drop the STEM podcast30. Novel PROTAC & Bacteriophage P1 Therapy on Pathogenic Bacteria - Jay IyerHere comes the 30th episode, y'all! Jay Iyer is a researcher in microbiology, a double ISEF finalist and an RSI 2020 finalist. Jay created a bacteriophage cocktail that showed outstanding efficacy in killing E.coli bacteria in meat. As part of his ISEF 2020 project, he developed a novel way of proteolysis in fighting against Alzheimer's Disease. He is also a First Place Division Challenge Winner at National Science Bowl, founder and CEO of the nonprofit organization "Mind Relief". Through Agape in Action, Jay travelled to Guatemala to assist in gynaecological treatments. He is invested in scientific advocacy fields, teaching the younger...
2020-04-2647 min
The D.O.P.E. Farm PodcastPatrick Henry "Liberty or Death" GWs Rule 22, Chickweed, Streamlight Protac
2020-01-1334 min
The Second is for Everyone PodcastEp49 Winter-WarriorsWe announce the date for the next 2A4E Diversity Shoot, give away the Patriot Patch Company January patch of the Month, discuss positive firearms legislation, review the Streamlight ProTac HX-L 1000 lumen flashlight, talk about real life heroes and more.
2019-02-071h 21
The Safety Solutions Academy PodcastBright Lights for Personal ProtectionDo you carry a light for personal defense? If you do, what light have you selected? How do you carry it? Where does it rank in importance in your EDC? In today’s episode Richard and I talk about things like: How Richard and I met in real life and social media safety The flashlight revolution The Beginnings of Flashlights Maglite Streamlight SL20 Rechargeable Surefire 6P Lumens is all the focus but there are more aspects to a quality light Candela - Candlepower “peak beam intensity” measures the largest reflected intensity. Lumens - Total amount of light - measures on...
2017-11-071h 48The Safety Solutions Academy » Podcast FeedBright Lights for Personal ProtectionDo you carry a light for personal defense? If you do, what light have you selected? How do you carry it? Where does it rank in importance in your EDC? In today's episode Richard and I talk about things like: How Richard and I met in real life and social media safety The flashlight revolution The Beginnings of Flashlights Maglite Streamlight SL20 Rechargeable Surefire 6P Lumens is all the focus but there are more aspects to a quality light Candela - Candlepower "peak beam intensity" measures the largest reflected intensity. Lumens - Total amount of light - measures...
2017-11-071h 48
Elite Man PodcastHow To Survive Any Type Of Disaster Scenario And Prep For The Future - Jim Cobb (Ep. 135)Jim Cobb, survivalist, author, and expert prepper, joins our show in this special episode of the Elite Man Podcast! Jim talks about how to prepare for any disaster or doomsday scenario and how to keep you and your loved ones safe! He shares with us his best tips for preparing for the event of something very bad happening and shares with us sound and practical advice for surviving. If you’re wondering how to keep yourself safe, prepare for any disaster that might strike in the future, and what survival skills you need to know, check this episode out no...
2017-09-051h 16
Alzheimer's SpeaksSensory Chair and More Improving HealthToday we are lucky to have Noel Wareing is an Ex Army Medic and Veteran who spent 12 and half years in the British Army treating people and running medical facilities all over the world. He is patient focused and believes everyone deserves a good standard of care. I am very excited to learn more about the Sensory Chair and other products provided by Apollo Healthcare International.
Contact Information For
http://apollo-healthcare.com/protac
noel@apollo-healthcare.com
Additional Resource Information:
Alzheimer’s Speaks Resource Website: https://www.alzheimersspeaks.com/
Keynote Speaker: https://www.al...
2016-08-0448 minAlzheimer's SpeaksSensory Chair and More Improving HealthToday we are lucky to have Noel Wareing is an Ex Army Medic and Veteran who spent 12 and half years in the British Army treating people and running medical facilities all over the world. He is patient focused and believes everyone deserves a good standard of care. I am very excited to learn more about the Sensory Chair and other products provided by Apollo Healthcare International. Contact Information For http://apollo-healthcare.com/protac noel@apollo-healthcare.com Additional Resource Information: Alzheimer’s Speaks Resource Website: https://www.alzheimersspeaks.com/ Keynote Speaker: https://www.al...
2016-08-0448 min
It's New Orleans: Out to LunchFighting Fit - Out to Lunch - It's New OrleansIf you ve ever had folks come visit you in New Orleans from out of town, they ve probably said, "If I lived here I d put on a hundred pounds." They re not the folks who come here to visit ProTac Fitness. Those folks say, "If I lived here I could benchpress another hundred pounds." Protac Fitness is a New Orleans business that trains people to get in shape for the US military and law enforcement. It s founder and CEO, Canaan Heard, joins Peter on this edition of Out to Lunch. Beth Winkler is also in the physical...
2016-05-0522 min